Announcements
Sidley Represents Neomorph in Its US$100 Million Series B Financing
April 15, 2026
Sidley represented Neomorph, Inc., a biotechnology company developing innovative molecular glue degraders, in its US$100 million Series B financing. The round was led by Deerfield Management, with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital. The proceeds from the financing will support Neomorph’s continued advancement of its proprietary platform and pipeline focused on discovering and developing molecular glue degraders targeting previously intractable diseases.
The Sidley team was led by Rosemary G. Reilly (Emerging Companies and Venture Capital) and included Rebecca Nauta (Emerging Companies and Venture Capital) and Matthew Dutton (Investment Funds).
連絡先
得意分野
Suggested News & Insights
Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private PlacementAugust 21, 2026The Wait is Over: SEC Proposes “Regulation Crypto Assets,” A Bespoke Offering Regime for Crypto Investment ContractsAugust 20, 2026Sidley Represents Clearlake Capital Group in Its Investment in Databricks’ US$5 Billion Funding RoundAugust 19, 2026Sidley Represents FormX in Its US$12.5 Million Series Seed FinancingAugust 11, 2026Sidley Represents Sapiom in US$35 Million Series A FinancingAugust 5, 2026Sidley Represents CAIS in Its US$170 Million Series D FinancingJuly 29, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


